Andreas H Groll Selected Research

Triazoles

1/2019	Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study.
1/2019	A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.
10/2017	Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.
2/2017	Clinical hepatotoxicity associated with antifungal agents.
12/2012	Results from a prospective, international, epidemiologic study of invasive candidiasis in children and neonates.
1/2004	Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
6/2003	Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andreas H Groll Research Topics

Disease

40	Infections 03/2024 - 03/2002
35	Neoplasms (Cancer) 04/2024 - 03/2006
31	Mycoses (Diseases, Fungus) 04/2024 - 03/2002
21	Invasive Fungal Infections 10/2019 - 03/2002
17	Aspergillosis 10/2023 - 01/2002
14	Neutropenia 07/2023 - 09/2007
13	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 07/2009
12	Candidiasis (Moniliasis) 08/2013 - 05/2002
11	Fever (Fevers) 12/2023 - 01/2010
11	Body Weight (Weight, Body) 03/2023 - 01/2002
9	Invasive Pulmonary Aspergillosis 01/2023 - 01/2002
9	Leukemia 01/2023 - 01/2017
7	Communicable Diseases (Infectious Diseases) 11/2023 - 03/2012
6	Graft vs Host Disease (Graft-Versus-Host Disease) 04/2024 - 01/2004
5	Lymphoma (Lymphomas) 10/2022 - 03/2014
4	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2022 - 01/2020
4	Pulmonary Aspergillosis 07/2015 - 01/2002
4	Invasive Candidiasis 08/2013 - 12/2005
3	Toxoplasmosis 12/2023 - 01/2018
3	Bacterial Infections (Bacterial Infection) 12/2023 - 01/2020
3	Sepsis (Septicemia) 07/2021 - 10/2019
3	Agranulocytosis (Granulocytopenia) 01/2021 - 03/2008
3	Bone Marrow Failure Disorders 02/2017 - 07/2009
2	COVID-19 03/2024 - 01/2023
2	Cysts 12/2023 - 03/2021
2	Lymphopenia (Lymphocytopenia) 07/2023 - 08/2017
2	Febrile Neutropenia 05/2023 - 02/2017
2	Opportunistic Infections (Opportunistic Infection) 10/2022 - 03/2021
2	Clinical Deterioration 12/2021 - 07/2021
2	Papilloma (Papillomatosis) 01/2021 - 11/2014
2	Colitis 01/2021 - 01/2015
2	Recurrent respiratory papillomatosis 01/2021 - 11/2014
2	Candidemia 12/2020 - 01/2017
2	Breakthrough Infections 12/2019 - 03/2006
2	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2018 - 02/2014
2	Necrosis 08/2017 - 04/2017
2	Lung Injury 06/2003 - 01/2002
2	Pulmonary Infarction 06/2002 - 01/2002

Drug/Important Bio-Agent (IBA)

15	liposomal amphotericin B FDA Link 12/2020 - 06/2002
12	Antifungal AgentsIBA 04/2024 - 07/2009
11	Voriconazole (Vfend)FDA LinkGeneric 11/2023 - 03/2002
11	EchinocandinsIBA 10/2023 - 01/2002
10	posaconazole FDA Link 01/2021 - 01/2004
10	Amphotericin B (Amphotericin)FDA LinkGeneric 12/2020 - 01/2002
9	galactomannanIBA 01/2023 - 01/2002
9	Micafungin (FK463)FDA Link 07/2015 - 06/2002
7	AntigensIBA 03/2024 - 01/2002
7	Anti-Bacterial Agents (Antibiotics)IBA 12/2023 - 10/2019
7	TriazolesIBA 01/2019 - 06/2003
7	Caspofungin (Cancidas)FDA Link 04/2013 - 01/2002
5	Biomarkers (Surrogate Marker)IBA 10/2019 - 04/2013
5	Fluconazole (Zonal)FDA LinkGeneric 12/2012 - 10/2004
4	Imatinib Mesylate (Gleevec)FDA Link 10/2022 - 02/2014
4	Rituximab (Mabthera)FDA Link 10/2022 - 08/2017
4	Immunosuppressive Agents (Immunosuppressants)IBA 12/2021 - 04/2013
3	VaccinesIBA 03/2024 - 03/2021
3	letermovirIBA 01/2024 - 01/2021
3	blinatumomabIBA 10/2022 - 03/2021
3	pembrolizumabIBA 10/2022 - 03/2021
3	Inotuzumab OzogamicinIBA 10/2022 - 03/2021
3	Monoclonal AntibodiesIBA 09/2021 - 04/2017
3	SuspensionsIBA 09/2020 - 08/2002
3	isavuconazoleIBA 01/2019 - 01/2017
2	venetoclaxIBA 04/2024 - 10/2022
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2023 - 01/2004
2	tisagenlecleucelIBA 10/2022 - 03/2021
2	nilotinib FDA Link 10/2022 - 09/2021
2	Dasatinib (BMS 354825)FDA Link 10/2022 - 09/2021
2	Gemtuzumab (Mylotarg)FDA Link 10/2022 - 03/2021
2	Brentuximab VedotinIBA 10/2022 - 03/2021
2	polyglucosanIBA 12/2021 - 11/2016
2	NivolumabIBA 09/2021 - 03/2021
2	Chimeric Antigen ReceptorsIBA 09/2021 - 03/2021
2	Basiliximab FDA Link 03/2021 - 08/2017
2	IpilimumabIBA 03/2021 - 08/2017
2	Alemtuzumab (Campath)FDA Link 03/2021 - 08/2017
2	Abatacept (Orencia)FDA Link 03/2021 - 08/2017
2	Anti-Infective Agents (Microbicides)IBA 03/2021 - 02/2012
2	Bevacizumab (Avastin)FDA Link 01/2021 - 11/2014
2	Acyclovir (Aciclovir)FDA LinkGeneric 10/2019 - 01/2010
2	Proteins (Proteins, Gene)FDA Link 08/2017 - 04/2017
2	CytokinesIBA 04/2017 - 08/2013
2	AzolesIBA 07/2015 - 03/2014
2	PolyenesIBA 12/2012 - 12/2003
2	BilirubinIBA 01/2012 - 03/2002
2	2- amino- 4- methylenecyclopentane- 1- carboxylic acidIBA 05/2005 - 10/2004
2	Isoleucine-tRNA LigaseIBA 05/2005 - 10/2004
2	ER 30346 (ravuconazole)IBA 04/2004 - 06/2003
1	midostaurinIBA 04/2024

Therapy/Procedure

48	Therapeutics 04/2024 - 01/2002
27	Hematopoietic Stem Cell Transplantation 07/2023 - 01/2004
19	Cell Transplantation 01/2024 - 03/2020
18	Drug Therapy (Chemotherapy) 01/2023 - 01/2004
11	Stem Cell Transplantation 12/2023 - 01/2008
10	Transplantation 12/2023 - 01/2004
4	Catheters 12/2020 - 05/2010
3	Chemoprevention 01/2019 - 03/2012
3	Salvage Therapy 01/2006 - 01/2004
2	Immunotherapy 04/2024 - 08/2013
2	Central Venous Catheters 01/2021 - 01/2011